{"id":"placebo-aspirine-clopidogrel","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Bleeding"},{"rate":"5-10","effect":"Gastrointestinal upset (aspirin)"},{"rate":"3-7","effect":"Dyspepsia"},{"rate":"1-3","effect":"Rash (clopidogrel)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin irreversibly inhibits cyclooxygenase enzymes, reducing thromboxane A2 production and platelet aggregation. Clopidogrel is a thienopyridine that irreversibly blocks the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet activation and aggregation. Placebo serves as the control arm. These agents work through distinct mechanisms to inhibit platelet function and reduce thrombotic events.","oneSentence":"This is a combination study comparing placebo, aspirin (a non-selective cyclooxygenase inhibitor), and clopidogrel (a P2Y12 platelet receptor antagonist) for antiplatelet effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:45.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Stroke prevention"},{"name":"Peripheral arterial disease"}]},"trialDetails":[{"nctId":"NCT00152646","phase":"PHASE4","title":"Platelets Induced Vasodilation, in Vitro and in Vivo Study","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2005-03","conditions":"Peripheral Arterial Disease","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":493,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo, aspirine, clopidogrel","genericName":"placebo, aspirine, clopidogrel","companyName":"University Hospital, Angers","companyId":"university-hospital-angers","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination study comparing placebo, aspirin (a non-selective cyclooxygenase inhibitor), and clopidogrel (a P2Y12 platelet receptor antagonist) for antiplatelet effects. Used for Acute coronary syndrome, Stroke prevention, Peripheral arterial disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}